Open AccessTumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
Author(s) -
Hao Wang,
Shanhao Chen,
Die Meng,
Chunyan Wu,
Junjie Zhu,
Minlin Jiang,
Jing Ning,
Shengyu Wu,
Lijia Wu,
Jingjie Li,
Bin Chen,
Sha Zhao,
Wei Li,
Jia Yu,
Qiyu Fang,
Jun Zhu,
Wencheng Zhao,
Yayi He,
Caicun Zhou
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s294993
Subject(s) - kras , adenocarcinoma , immune system , phenotype , medicine , lung cancer , oncology , exact test , univariate analysis , mutation , cancer , logistic regression , cancer research , multivariate analysis , immunology , gene , biology , genetics , colorectal cancer
Nowadays, immune checkpoint blockades (ICBs) have been extensively applied in non-small cell lung cancer (NSCLC) treatment. However, the outcome of anti-program death-1/program death ligand-1 (anti-PD-1/PD-L1) therapy is not satisfying in EGFR -mutant lung adenocarcinoma (LUAD) patients and its exact mechanisms have not been fully understood. Since tumor mutation burden (TMB) and tumor immune phenotype had been thought as potential predictors for efficacy of ICBs, we further studied the TMB and immune phenotype in LUAD patients to explore potential mechanisms for poor efficacy of ICBs in EGFR positive mutated patients and to find possible factors that could impact the tumor immune phenotype which might uncover some new therapeutic strategies or combination therapies.